Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Cost-utility of aspirin and proton pump inhibitors for primary prevention.

Earnshaw SR, Scheiman J, Fendrick AM, McDade C, Pignone M.

Arch Intern Med. 2011 Feb 14;171(3):218-25. doi: 10.1001/archinternmed.2010.525.

2.

Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention.

Saini SD, Schoenfeld P, Fendrick AM, Scheiman J.

Arch Intern Med. 2008 Aug 11;168(15):1684-90; discussion 1691. doi: 10.1001/archinte.168.15.1684.

PMID:
18695083
3.

Gastroprotection in low-dose aspirin users for primary and secondary prevention of ACS: results of a cost-effectiveness analysis including compliance.

de Groot NL, van Haalen HG, Spiegel BM, Laine L, Lanas A, Focks JJ, Siersema PD, van Oijen MG.

Cardiovasc Drugs Ther. 2013 Aug;27(4):341-57. doi: 10.1007/s10557-013-6448-y.

PMID:
23417566
4.

Cost-Effectiveness of Proton Pump Inhibitor Co-Therapy in Patients Taking Aspirin for Secondary Prevention of Ischemic Stroke.

Takabayashi N, Murata K, Tanaka S, Kawakami K.

Pharmacoeconomics. 2015 Oct;33(10):1091-100. doi: 10.1007/s40273-015-0289-4.

PMID:
25995130
5.

Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention.

Saini SD, Fendrick AM, Scheiman JM.

Aliment Pharmacol Ther. 2011 Jul;34(2):243-51. doi: 10.1111/j.1365-2036.2011.04707.x. Epub 2011 May 25.

6.

A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.

Hsiao FY, Tsai YW, Huang WF, Wen YW, Chen PF, Chang PY, Kuo KN.

Clin Ther. 2009 Sep;31(9):2038-47. doi: 10.1016/j.clinthera.2009.09.005.

PMID:
19843493
7.

Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.

Pignone M, Earnshaw S, Tice JA, Pletcher MJ.

Ann Intern Med. 2006 Mar 7;144(5):326-36.

PMID:
16520473
8.

Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.

Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW, Orhewere M, Gisbert J, Sharma VK, Rostom A, Moayyedi P, Forman D.

Health Technol Assess. 2007 Dec;11(51):iii-iv, 1-164. Review.

9.

Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.

Vaduganathan M, Bhatt DL, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Cannon CP; COGENT Investigators..

J Am Coll Cardiol. 2016 Apr 12;67(14):1661-71. doi: 10.1016/j.jacc.2015.12.068. Epub 2016 Mar 21.

11.

Analysis of gastrointestinal prophylaxis in patients receiving dual antiplatelet therapy with aspirin and clopidogrel.

Morneau KM, Reaves AB, Martin JB, Oliphant CS.

J Manag Care Pharm. 2014 Feb;20(2):187-93.

12.
15.

Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.

Kourlaba G, Fragoulakis V, Maniadakis N.

Appl Health Econ Health Policy. 2012 Jul 1;10(4):261-71. doi: 10.2165/11633820-000000000-00000.

PMID:
22667992
16.

Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events.

Sylvester KW, Cheng JW, Mehra MR.

Vasc Health Risk Manag. 2013;9:245-54. doi: 10.2147/VHRM.S44265. Epub 2013 May 16. Review.

17.

Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.

Coleman CI, Straznitskas AD, Sobieraj DM, Kluger J, Anglade MW.

Am J Cardiol. 2012 Apr 1;109(7):1020-5. doi: 10.1016/j.amjcard.2011.11.034. Epub 2012 Jan 3.

PMID:
22221944
18.

Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.

Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, Sudlow C, Henderson R, Hawkins N, Riemsma R.

Health Technol Assess. 2004 Oct;8(38):iii-iv, 1-196. Review.

19.

Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study.

Ray WA, Murray KT, Griffin MR, Chung CP, Smalley WE, Hall K, Daugherty JR, Kaltenbach LA, Stein CM.

Ann Intern Med. 2010 Mar 16;152(6):337-45. doi: 10.7326/0003-4819-152-6-201003160-00003.

20.

Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.

Gaspoz JM, Coxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink MG, Goldman L.

N Engl J Med. 2002 Jun 6;346(23):1800-6.

Supplemental Content

Support Center